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ABSTRACT
Objectives: Previously,  in an animal study we showed that 
N-acetylcysteine (NAC) could decrease deoxycholate amphotericin B 
(DAmB) induced renal tubular apoptosis. In this clinical study, 
we aimed to evaluate the efficacy of NAC in preventing acute 
kidney injury (AKI) in febrile neutropenic patients with invasive 
pulmonary aspergillosis treated with DAmB. 
Patients and Methods:  Thirty-three patients were included in 
the study. 17 patients were randomly placed into the DAmB group 
and 16 were randomly placed into the DAmB plus NAC group. 
Results: The characteristics of patients, durations and 
cumulative doses of DAmB, concurrent nephrotoxic drugs and 
basal serum creatinine (SCr) levels of patients were similar. 
Occurrence of a 1.5 fold or greater increase in the concentration 
of basal SCr and serum electrolytes were observed prospectively. 
The overall AKI was found in 13 patients (76.4%) in DAmB 
group and 6 patients (37.5%) in combination group (P = 0.024). 
No significant difference was observed in hypokalemia incidence 
between the groups (87.5 % in combination vs. 94.1 % in DAmB 
only groups). 
Conclusion: This clinical pilot study showed that NAC may be 
a promising anti-oxidant agent to decrease DAmB-induced AKI in 
febrile neutropenic patients.
Keywords: Amphotericin B, Acute kindey injury, N-acetyl cysteine, 
Febrile neutropenia
ÖZ
Amaç: Daha önceki bir hayvan çalışmasında, N-asetilsistein 
(NAC)’in amfoterisin B (DAmB) ilişkili renal tubuler hasarı 
azalttığını gösterdik. Bu çalışmada, DAmB ile tedavi edilen invaziv 
pulmoner aspergillozlu febril nötropenik hastalarda NAC’in akut 
böbrek hasarı  (ABH)’nı önlemedeki etkisini göstermeyi amaçladık. 
Hastalar ve Yöntem: Otuz üç hasta çalışmaya dahil edildi. 
Randomize olarak 17 hasta  DAmB grubuna ve 16 hasta  DAmB 
ve NAC grubuna alındı. 
Bulgular: Hastaların karakteristik özellikleri, DAmB tedavi 
süreleri ve kümülatif dozları, ek olarak aldıkları nefrotoksik ilaç ve 
bazal serum kreatinin (SCr) değerleri benzer bulundu. Bazal SCr 
değerlerinde 1.5 kat veya daha fazla artış ve serum elektrolitleri 
prospektif olarak gözlemlendi. ABH,  DAmB  grubunda 13 hastada 
( %76,4), kombine grupta 6 hastada (%37,5) görüldü (P = 0,024). 
İki grup arasında hipokalemi insidansında anlamlı fark saptanmadı 
(Kombine grupta % 87,5, DAmB grubunda % 94,1). 
Sonuç: Bu klinik pilot çalışma,  NAC’in febril nötropenik 
hastalarda,  DAmB ilişkili ABH’nı azaltmada umut vaad eden bir 
antioksidan ajan olduğunu göstermektedir.  
Anahtar kelimeler: Amfoterisin B, Akut böbrek hasarı, 
N-asetilsistein, Febril nötropeni
Introduction
Invasive aspergillosis is frequently seen in febrile neutropenic 
patients, and immediate treatment such as; widely used 
antifungal, amphotericin B (AmB), has shown to decrease 
its mortality [1]. Due to the high incidence of nephrotoxicity 
with its deoxycholate form (DAmB), lipid formulations 
are increasingly preferred in developed countries [2]. The 
mechanism of DAmB nephrotoxicity has not been fully 
elucidated, however, Varlam et al. has demonstrated that 
AmB has a dose-dependent apoptotic effect in renal tubular 
cells of rats [3]. 
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The antioxidant N-acetylcysteine (NAC), a 
pharmaceutical primarily used as a mucolytic agent, has 
also been used to prevent radio - contrast nephrotoxicity 
in patients who have undergone coronary angioplasty 
procedures due to its possible anti-apoptotic effect [4-6]. We 
have previously demonstrated in an animal study that renal 
tubular apoptosis caused by DAmB, is significantly reduced 
by the concomitant use of NAC [7]. These encouraging 
findings prompted us to perform this clinical study, in which 
we aimed to demonstrate NAC’s possible beneficial effect 
in DAmB induced acute kidney injury (AKI), in patients 
who are under treatment of DAmB for invasive pulmonary 
aspergillosis.
Patients and Methods
This study is a prospective, unblinded and randomized 
controlled study performed in Marmara University Hospital, 
between April 2010 and December 2012. Febrile neutropenic 
patients ( > 18 years old), with hematological malignancies 
who were candidates for treatment with DAmB due to 
suspected or proven invasive fungal infections [8] were 
randomly assigned to either a group receiving DAmB, or to 
a group receiving a combination of DAmB and NAC. Any 
patient with a history of DAmB or NAC allergy, or who had 
received DAmB in the three months prior to recruitment, or 
with any of the confounding comorbidities including renal 
disease or basal SCr above 1.1 mg/dL (upper limits of normal 
laboratory value), cardiac disease, chronic liver disease, 
was excluded.  All participating patients were required to 
sign an informed consent form prior to enrollment. This 
study has been approved by the Marmara University Ethics 
Committee.
Drug doses were: 1 mg/kg/day of DAmB administered 
by intravenous infusion over 2 hours; and oral NAC 600 mg 
given three times a day. Before the first dose of DAmB, all 
patients were premedicated with 500 mg oral paracetamol, 
45.5mg/2 mL intravenous pheniramine and 20 mg oral 
prednisolone to avoid possible infusion-related reactions 
such as fever and rigor. Renal function tests, SCr, blood 
urea nitrogen (BUN), complete blood count and electrolytes 
(sodium, potassium) were measured before the onset of 
DAmB therapy and then repeated everyday throughout the 
therapy. Liver function as well as calcium and magnesium 
levels were measured before the therapy and then two times 
a week. A serum galactomannan antigen test was performed 
two times a week through the neutropenic period, and 
computerized tomography (CT) imaging was performed 
when the patient tested positive for galactomannan 
antigen or in the case of clinical suspicion of invasive 
fungal infections. We recorded the concomitant usage of 
any potential nephrotoxic drug (e.g., aminoglycosides, 
vancomycin, ganciclovir or cyclophosphamide), and also 
recorded other side effects such as fever, chills, coughing 
and infusion reactions. 
DAmB induced acute kidney injury (AKI) was defined 
as an increase of SCr concentration during the therapy to 
greater than or equal to 1.5 times of basal SCr, according to 
the Kidney Disease Improving Global Outcomes (KDIGO) 
clinical practice guideline for acute kidney injury [9]. The 
primary outcome of the study was the AKI while receiving 
DAmB therapy. The antifungal therapy was discontinued 
if a patient develops AKI, in such cases an alternative 
antifungal agent was prescribed. Patients who developed 
hypokalemia with serum potassium levels below or equal 
to 3.0 mEq/L, or those who developed symptoms, were also 
given supplemental intravenous potassium. DAmB therapy 
was discontinued in patients with refractory hypokalemia. 
Statistical analysis 
Chi squared tests were used for comparison of categorical 
variables, and nonparametric Kruskal-Wallis tests were 
used for comparison of continuous variables. A multivariate 
analysis was performed for the prediction of nephrotoxicity. 
In the logistic regression model, age, body mass index, 
gender, nephrotoxic drug use, and DAmB usage with or 
without NAC were included as independent variables. The 
statistical analysis was performed using STATA, version 11 
(Texas, USA). Statistical significance was set as P < 0.05.
Results
Thirty-three patients were included in the study: 17 
patients were randomly placed into the DAmB group 
and 16 were randomly placed into the DAmB plus NAC 
(combination) group. Table I shows the details of the 
patients’ characteristics and the results of the study. No 
significant differences were noted between the study groups 
with respect to age, underlying diseases, cumulative dose 
of DAmB, concurrent nephrotoxic agent usage, and basal 
SCr values. The DAmB group received treatment for a mean 
of 9.3 days, in comparison to 9.6 days for the combination 
group (P = 0.82).
The overall AKI was found in 13 (76.4%) of 17 patients 
in DAmB group and 6 (37.5%) of 16 patients in combination 
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group (P = 0.024). These results indicate that addition of 
NAC significantly decreased DAmB-induced AKI. A 
multivariate analysis revealed that DAmB usage without 
NAC was associated with a 9.77 fold rise in AKI (P = 0.011). 
Note that hypokalemia was seen in 16 (94%) patients in the 
DAmB group and in 14 (87.3%) patients in the combination 
group (P = 0.509).
The treatment in the study was stopped in 4 patients in the 
combination group due to refractory hypokalemia depending 
DAmB, skin reaction, refractory cough and gastrointestinal 
intolerance due to NAC. The refractory cough, which 
caused hemoptysis secondary to thrombocytopenia, was 
probably related to the administration of NAC; the coughing 
diminished after NAC was ceased. One patient in the 
combination group and two patients in the DAmB group 
were switched to another antifungal agent due to progression 
according to CT findings and worsening clinical conditions. 
In the DAmB group, therapy was stopped in one patient 
because of nephrotoxicity and refractory hypokalemia. 
Six patients (35%) in the DAmB group (2 due to 
probable fungal pneumonia, 2 due to bacterial sepsis, and 
2 due to unidentified causes) and five patients (31%) in the 
combination group (2 due to probable fungal pneumonia, 
2 due to bacterial sepsis and one due to intracranial 
hemorrhage) died. Among these patients, nephrotoxicity 
was observed in one patient in the combination group and in 
3 patients in the DAmB group, attributable fatality analysis 
was not performed because of the low number of the patients 
in this set.
Table I. Comparison of patient characteristics and study results
Characteristics and study results DAmB alone
(n = 17)
DAmB + NAC combination (n = 16) P value
Age (yr), mean, range 43.94 (14.41), 
18 - 73
42.25 (14.84), 
19 - 67
0.742
Gender 0.829
                                         Male 10 10
                                             Female   7   6
Weight (kg) mean (SD), range 67.6 (11.8), 44 - 86 66.5 (11.9), 50 - 90 0.794
Body mass index mean (SD), range ± SD 24.65 (4.091), 
17.58 - 30.70
24.49 (4.041),
18.94 - 30.70
0.909
Underlying hematological malignancy
Acute lymphocytic leukemia   1 5
Acute myelocytic leukemia 12 7
Lymphoma   2 3
Stem cell transplantation   1 (autologous) 2 (allogeneic)
Myelodysplastic syndrome /other   2 1
Baseline neutrophils < 500/mm3   14/17 12/16
Reason to use antifungal therapy
Empirical   3   5
Pre - emptive 14 11
Amphotericin B therapy
Cumulative dose (mg), mean ± SD 637.35 ± 235.22 622.81 ± 237.30 0.860
Duration (days), mean ± SD 9.3 ± 2.97 9.6 ± 3.91 0.823
Concurrent nephrotoxin usage 11/17 10/16 0.895
Baseline SCr value (mg/dL) 0.64 (0.3 - 1.08) 0.59 (0.2 - 1.08) 0.438
Acute kidney injury
Increase in SCr > 1.5 x baseline   SCrS 13/17 6/16 0.024
Maximum SCr (mean ± SD) 1.25 ± 0.532 0.91 ± 0.351 0.0387
Hypokalemia 16/17 14/16 0.509
Median day to acute kidney    injury 7 (3 - 15) 6.5 (3 - 12) 0.915
Median cumulative dosage of DAmB when 
acute kidney injury developed
412 (183 - 1050) 335 (250 - 732) 0.594
Mortality 6 5 0.805
DAmB: deoxycholate amphotericin B, NAC: N-acetylcysteine, SD: standard deviation, SCr:serum creatinine
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Discussion
DAmB, with its wide antifungal spectrum, is one of 
the agents used in the treatment and/or empiric therapy 
for invasive fungal infections in febrile neutropenic 
hematology–oncology patients. Because of the high 
incidence of nephrotoxicity and infusion reactions, use of 
this form of the drug is often limited [10]. Currently, most 
guidelines recommend lipid formulations of AmB instead of 
DAmB [8,10]. According to the Turkish Ministry of Health 
Directives, however, DAmB is approved as the first – line 
antifungal drug for febrile neutropenic patients, and only 
when side effects occur, health professionals in Turkey are 
able to use alternative antifungal agents such as voriconazole 
or lipid formulations of AmB. Therefore, unfortunately our 
patients are face to face with these possible side effects of 
DAmB and in this prospective study, aiming to investigate 
a possible preventive measure, we were able to demonstrate 
that the NAC therapy significantly reduces DAmB induced 
AKI, yet has no beneficial effect in reducing hypokalemia 
and infusion related side effects. 
As mentioned above, infusion reactions, hypokalemia 
and nephrotoxicity are some of the most important side 
effects of DAmB. Premedications such as paracetamol, 
steroids and anti-histamines have usually been given to 
prevent infusion reactions, and potassium supplements 
have been given for hypokalemia. Among the side effects, 
however, nephrotoxicity is the most concerning as it 
increases the length of hospital stays and health costs, as well 
as increasing morbidity and mortality rates [12]. DAmB-
induced nephrotoxicity has been reported at rates between 
49% and 65% in different studies [13-15]. Wingard et al., 
evaluated the nephrotoxicity of DAmB in patients treated for 
proven or suspected aspergillosis and they found a doubling 
of the basal SCr values in 53% of the patients, 14.5% of 
which required hemodialysis [13]. In our study, 13 of 17 
patients (76.4%) treated with DAmB experienced a 1.5 fold 
increase in basal SCr levels. Because of the ethical points 
and available more qualified antifungal agents, in case of 
rise of SCr 1.5 fold of the basal levels and rise above 1.1 
mg/dl we switched DAmB to another non-toxic antifungal 
agent. So we could not be able to observe patients until 2 or 
more folds of SCr above basal levels. None of the patients 
required hemodialysis probably due to early termination of 
DAmB therapy immediately when AKI developed.  
Several procedures aimed to decrease DAmB 
nephrotoxicity have been tested, such as infusion with 
intralipid solutions, prolonging infusion time, and the 
addition of low-dose dopamine or mannitol, however, none 
of them have provided satisfactory results [16-20]. The high 
rate of nephrotoxicity has led to the development of AmB 
formulations in three different lipid bases: lipid complex, 
colloidal dispersion, and liposomal [21]. While lipid 
formulations of AmB were found to be less nephrotoxic 
than other formulations of the drug, these formulations do 
not completely eliminate nephrotoxicity. In a randomized 
double-blind study of more than six hundred patients 
that compared liposomal AmB (AmB-L) and AmB-D for 
empirical treatment in persistent febrile neutropenic patients, 
nephrotoxicity rates were 18.7% and 33.7% respectively 
[15]. Although lower rates of nephrotoxicity are observed 
with lipid formulations than with DAmB, the cost of these 
agents is substantial, and access may be challenging in 
resource-limited settings. 
DAmB-induced nephrotoxicity is secondary to renal 
vasoconstriction, which leads to tubular damage and a 
decreased glomerular filtration rate [22,23]. In an animal 
study, Varlam et al., demonstrated that AmB has a dose-
dependent apoptotic effect in renal tubular cells of rats, 
with ensuing nephrotoxicity [3]. In the same study, they 
also showed that AmB-induced apoptosis and the resulting 
nephrotoxicity could be reduced by the concomitant use of 
recombinant human insulin-like growth factor 1 (rhIGF-1), 
an anti-apoptotic agent. In our previous studies, we have 
found that rats that received NAC concomitantly with 
DAmB had significantly decreased levels of AmB-induced 
renal tubular cell apoptosis compared to animals that only 
received DAmB [7]. 
These animal-study results are consistent with the 
results of the current clinical pilot study which suggest that 
NAC, probably with its anti-apoptotic effect, significantly 
decreases DAmB   induced AKI. Cumulative DAmB doses 
and concurrent nephrotoxin use was similar between the 
study groups. Incidence of hypokalemia, however, was 
similar in both the combination and DAmB only groups (see 
above and Table I) suggesting that NAC has no preventive 
effect on hypokalemia. In a recently published randomized, 
double-blinded, placebo-controlled, clinical study, efficacy 
of the NAC in prevention of DAmB induced electrolyte 
imbalances was evaluated. They showed that NAC has no 
preventive effect against hypokalemia or hypomagnesemia 
as we found [24]. They also evaluated the nephrotoxicity 
as a secondary end point in their study and they defined the 
nephrotoxicity as either doubling of SCr from the baseline 
value or ≥50 % decrease in glomerular filtration rate. 
Although the rate of DAmB nephrotoxicity was higher in 
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the placebo than in the NAC group (60 % versus 40 %), this 
difference was not statistically significant (P = 0.209). In 
our study AKI was defined as 1.5 fold or more increase in 
basal SCr and also we used total 1800 mg of NAC per day 
while they used 1200 mg in a day. Major problem at this 
point is the standardization of definition of drug-induced 
nephrotoxicity. In 2002, the Acute Dialysis Quality Initiative 
(ADQI) was developed RIFLE classification system for the 
uniform definition of AKI in the world [25]. A few years 
later Acute Kidney Injury Network (AKIN group) proposed 
the AKIN criteria for the definition of AKI [26]. Finally 
in 2012 the Kidney Disease Improving Global Outcomes 
(KDIGO) released their clinical practice guidelines for acute 
kidney injury (AKI), which build off of the RIFLE criteria 
and the AKIN criteria [9]. KDIGO defines AKI as any of the 
following: an increase in serum creatinine by 0.3mg/dL or 
more within 48 hours or increase in SCr to 1.5 times baseline 
or more within the last 7 days or urine output less than 0.5 
mL/kg/h for 6 hours. In our study we accepted AKI as 1.5 
fold rise of basal SCr and because of available more potent 
and less nephrotoxic antifungal agents we changed DAmB 
to voriconazole, liposomal AmB or caspofungin. That is 
why we could not be able to observe 2 or 3 fold rise of SCr 
in our study.   
Major limitations of our study is the open lable design 
of the study and the low number of patients. Given the 
promising results presented here, this study should be 
repeated with a larger number of patients. In addition, future 
research could expand upon the current work in several 
ways. For example, different NAC dosages could be tested 
to determine the ideal dosage. Also, whereas our study group 
consisted of high-risk neutropenic patients, future work 
could be extended to non-neutropenic candidemic patients 
that are given lower DAmB dosages. It may also be possible 
to consider blinded experiments rather than the current open 
study design, and to observe patients for a longer duration of 
time than we had. Also note that a refractory cough leading 
to hemoptysis was observed in one patient receiving NAC 
in the current study, and the safety of this treatment should 
be evaluated in a larger group of patients. In conclusion, in 
this study we demonstrated that NAC reduces AMB induced 
AKI, therefore, we suggest that in the case of DAmB use, 
addition of NAC may be beneficial, yet broader studies are 
needed to support this recommendation.
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